Dynamo Platform
Provider 
Founded 2016
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public

Dynamo Platform is Relay Therapeutics' Motion-Based Drug Design platform for finding novel allosteric binding sites on validated targets.
The Dynamo Platform is Relay Therapeutics' Motion-Based Drug Design engine, which uses protein motion to identify potential novel allosteric binding sites on well-validated targets. By analyzing how proteins move, the platform reveals binding opportunities that static structures miss.
Dynamo supports structure-based design, enabling Relay Therapeutics to translate motion-derived insights into small-molecule drug candidates. The platform underpins the company's discovery programs against disease-relevant protein targets.
Adds products that compete with one of Dynamo Platform’s direct competitors but not with Dynamo Platform itself. They are shaded, and Linked Through names the direct competitor each one competes with.
| Attribute | Dynamo Platform | Induced Allosteric Drug Discovery Platform | Allosteric Inhibitor Screening + Synthetic Lethality Discovery Platform | Magellan Platform | Smart Allostery Platform | |
|---|---|---|---|---|---|---|
| Linked Through | — | Direct competitor | Induced Allosteric Drug Discovery Platform | Induced Allosteric Drug Discovery Platform | Induced Allosteric Drug Discovery Platform | |
| Provider | ||||||
| Founded | 2016 | 2015 | 2020 | 2017 | 2017 | |
| Sells To | Enterprise | Enterprise, Government | Enterprise | Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Recurring | Recurring, Software | Recurring, Software | Recurring, Software | |
| Ownership | Public | Public | Private | Venture-backed | Private equity-backed, Venture-backed |
Provider 
Founded 2016
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 2015
Sells To Enterprise, Government
Pricing Model Recurring
Ownership Public
Linked Through Induced Allosteric Drug Discovery Platform
Provider 
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Linked Through Induced Allosteric Drug Discovery Platform
Provider 
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
Linked Through Induced Allosteric Drug Discovery Platform
Provider 
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private equity-backed, Venture-backed


Smart Allostery Platform is HotSpot Therapeutics' allosteric drug discovery platform for targeting disease-driving proteins.


Gain Therapeutics platform using artificial intelligence and virtual screening for allosteric drug discovery.


Allosteric screening and synthetic lethality platforms with 200k library.
Smart Allostery Platform is HotSpot Therapeutics' allosteric drug discovery platform for targeting disease-driving proteins.

Gain Therapeutics platform using artificial intelligence and virtual screening for allosteric drug discovery.

Allosteric screening and synthetic lethality platforms with 200k library.
